Vertex Pharmaceuticals Inc
NASDAQ: VRTX
$494.61
-$5.27 (-1.1%)
Closing Price on November 6, 2024
VRTX Articles
These are the top Wall Street analyst upgrades, downgrades and initiations for Wednesday, June 25, 2014. They include Apple, Coach, J.C. Penney, Micron Technology, Whole Foods and Vertex...
Published:
Vertex Pharmaceuticals has reported that two Phase 3 studies of its lumacaftor cystic fibrosis drug in combination with its Kalydeco ivacaftor showed positive results. Shares spikes on the news.
Published:
Last Updated:
In a new report, the analysts at health care boutique Leerink highlight numerous upcoming catalysts for some top stocks in the sector. Catalysts may move the stocks sharply either way, depending on...
Published:
Here are the four top biotech names we found that all have hepatitis C drugs in their current pipelines at one stage or another and that could be the next takeover targets.
Published:
In a new research report, the pharmaceutical and biotech analysts at RBC highlight their meetings with a group of six physicians. They favor four top stocks now as best positioned for continued...
Published:
ThinkstockIn just a matter of days, the S&P 500 managed to produce a sell-off of more than 6%. The equity strategy team at Jefferies concede that the recent correction in share prices has raised...
Published:
Many bears on Wall Street say that biotech stocks are overvalued, but many trade in line with historical valuations. In a new research report, Cowen highlights upcoming catalysts that could send some...
Published:
Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across the board. Investors who...
Published:
The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility that some of the top names may also become takeover targets this year.
Published:
Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going forward but can stay intact. They think the fundamental backdrop is...
Published:
Baird offers an eclectic and interesting list for investors. A top regional firm, it tends to dig a little deeper, looking for ideas with not only growth potential, but catalysts. The usual big cap...
Published:
These are the top analyst upgrades, initiations and positive analyst research calls seen from Wall Street on Monday, January 6.
Published:
Last Updated:
The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.
Published:
ThinkstockIdenix Pharmaceuticals Inc. (NASDAQ: IDIX) was the biggest gainer of all listed stocks on Friday with a rally of 40%. Its trading volume of almost 9.2 million shares was almost eight-times...
Published:
ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their...
Published:
Last Updated: